Αποτελέσματα Αναζήτησης
8 Νοε 2023 · In this article, we highlight success and ongoing challenges in three areas of high activity in gene therapy: inherited blood cell diseases by targeting hematopoietic stem cells, malignant...
- Translating p53-based therapies for cancer into the clinic
In this Review, we present these ongoing clinical trials and...
- Translating p53-based therapies for cancer into the clinic
Gene therapy for cancer treatment has good progress in the last three decades, few drugs approved, while others are still in trials. Relatively gene therapy has better safety with tolerable adverse effects than chemotherapy for the treatment of cancer.
1 Σεπ 2022 · After reviewing 1908 gene therapy clinical trials from 2010 to October 2020, it was concluded that they could be classified into three major fields: cancers, monogenic and polygenic disorders (genetic disorders), infections, and other studies.
1 Ιουν 2022 · Summary. A patient with progressive metastatic pancreatic cancer was treated with a single infusion of 16.2×10 9 autologous T cells that had been genetically engineered to clonally express two...
Although gene therapy was initially used to treat genetic diseases, cancer now has the greatest number of gene therapy clinical trials. Changes in gene therapy strategies, particularly in pioneering countries in this field, may point to the direction of future clinical products.
29 Ιαν 2024 · In this Review, we present these ongoing clinical trials and emerging approaches to re-evaluate the current state of knowledge of p53-based therapies for cancer.
28 Μαΐ 2021 · SGT-53 is an investigational product for tumor-targeted TP53 gene therapy that has completed phase Ia/Ib trials [Senser et al (2013), Mol Ther 21:1096; Pirollo et al (2016) Mol Ther 24:1697]. Methods: Here we provide an interim analysis of a Phase II trial (SGT53-02-1; NCT02340117) combining SGT-53 with gemcitabine/nab-paclitaxel (GEM/ABX).
